Answers are grounded in this paper and cite their sources.
The usual, standard pharmacological preparation of the endometrium in oocyte donation (OD) cycles deals with the administration of oestrogens for the proliferative phase followed by oestrogens coupled with progesterone for the secretive phase of the endometrium preparation.Due to our previous successful experience with some low responders where we shifted from human menopausal gonadotrophins (HMG) to oestrogens at around day 10 of therapy and we converted the cycle from an own oocyte to an oocyte donation cycle, it was decided to adopt this same protocol for planned OD cycles.Forty five recipient patients agreed to be treated with this new, alternative treatment and gave their written consent.After 10 days of HMG treatment, this therapy was replaced by oral oestrogens.However, six patients showed by ultrasound the development of a certain number of follicles and it was decided to continue with the HMG and proceed to ovum pick up (OPU) and in vitro fertilization (IVF) of their own oocytes.Two obtained a clinical pregnancy (33%).In the remaining thirty nine patients, there was no follicle development and the HMG was replaced after ten days of treatment by oral oestrogens and by OD.Twenty two clinical pregnancies were obtained (56%).Acceptance of oocyte donation is a difficult decision for the patients.This described alternative pharmacological protocol gives to the patients the opportunity to ascertain whether their own ovaries have responded to HMG or not.In the affirmative, the HMG treatment may be continued and OPU and IVF may be performed with their own oocytes.Otherwise, HMG is stopped after 10 days of treatment and replaced by oestrogens in order to complete the proliferative phase of the endometrium and proceed with the OD.The results obtained with this new pharmacologic protocol in OD, 56%, was slightly higher than the results obtained in the same time period with the standard oestrogens/progesterone protocol for OD: eleven clinical pregnancies out of twenty four cases (46%).In addition, the new here described protocol is more acceptable by the majority of patients, since they may decide at the last minute whether to use own oocyte or donated oocytes.Conversely, in planned OD, with oestrogens administered from the very start of the treatment, the use of donated oocytes is planned from the beginning and there is no place for a possible conversion to own oocytes.With the exception of genetic indications and absolute absence of ovarian reserve, there is always a possibility, though small, that patients candidate for OD may develop own oocytes and the depicted protocol gives a chance to these patients who reluctantly accept OD as a last and ultimate resort.Whether this new approach to OD is better than the usual complete hormonal replacement protocol needs a prospective statistically well designed study.
No takes yet. Share an insight, caveat, or question.
Andriamaro et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: